Summary Nebulised iloprost is established therapy of severe pulmonary hypertension; however, the effects on the bronchoalveolar compartment have not been investigated so far. We studied the short-and long-term effects of nebulised iloprost on pulmonary function tests and gas exchange in 63 patients with severe pulmonary hypertension (idiopathic n ¼ 17, chronic thromboembolism n ¼ 15, connective tissue disease n ¼ 12, congenital heart disease n ¼ 11, respiratory diseases n ¼ 8). Patients received iloprost in increasing dose up to 140 mg iloprost/24 h via an ultrasonic nebuliser.
Introduction
Nebulised iloprost is established in the therapy of pulmonary hypertension of different origin leading to a significant symptomatic, functional and haemodynamic improvement. 1 The nebulised application of prostanoid has the advantage of pulmonary selectivity leading to fewer systemic side effects and improved ventilation-perfusion ratio in the lung, in particular important in patients with underlying pulmonary parenchymal disorder. 2, 3 However, possible intrabronchial effects during nebulisation have not been investigated so far. Patients with pulmonary hypertension have an impaired gas exchange at rest and during exercise leading to an impaired oxygenation. 4 Furthermore, bronchial changes with peripheral airways obstruction have been described in patients with primary pulmonary hypertension. 5 Previous in vitro and in vivo studies of prostanoids in the bronchial compartment showed variable results. While some authors describe a bronchodilating activity of iloprost and prostacyclin in vivo and in vitro, 6, 7 other describe opposite results of inhaled prostacyclin in vivo, 8 and one report described bronchoconstrictive effects of inhaled prostacyclin in asthmatics. 9 Published studies on treatment with nebulised iloprost, using a range of 37.5-130 mg daily iloprost dose and different nebulisers, reported typical side effect as nausea, cough, flush, chest pain, and jaw pain. However, in none of these studies bronchoalveolar side effects have been further analysed. 1, [10] [11] [12] [13] Therefore, we evaluated the short-and longterm effects of nebulised iloprost on pulmonary function tests and pulmonary gas exchange in patients, who were newly commenced on nebulised iloprost therapy for treatment of severe pulmonary hypertension of different origin.
Patients and methods
We included 63 patients (28 male, 37 female, mean age 48 (16-83) years) with severe pulmonary hypertension or different origin. In total, 17 patients suffered from idiopathic pulmonary arterial hypertension (IPAH); 15 patients had chronic thromboembolic pulmonary hypertension (CTEPH), among them 6 patients with proximal vascular obstructions amenable for pulmonary thrombendarterectomy. In 12 patients, pulmonary arterial hypertension has been associated with connective tissue disease (CTD), and in 11 patients pulmonary arterial hypertension developed due to congenital heart disease (CHD). In 8 patients, pulmonary hypertension was associated with respiratory diseases (RD), among them 3 patients with idiopathic pulmonary fibrosis on chronic immuno-modulating therapy requiring long-term oxygen therapy, and 5 patients with COPD and emphysema in GOLD IV due to right heart failure despite treatment with oxygen supplementation, inhaled bronchodilators and diuretics. 14 Patients underwent pulmonary function tests, 6 min walking test with measurement of percutaneous oxygen saturation, and right heart catheterisation with Swanz-Ganz Catheter including measurement of cardiac output by thermodilution method at baseline and after 3 months therapy. At the follow-up 6 min walking test (6 MWT) and haemodynamic measurements and were performed at least 2 h after last iloprost inhalation.
After baseline examinations, all patients were newly started on treatment with nebulised iloprost using an ultrasonic jet nebuliser (Multisonic compact s , Schill Company, Germany) with an efficacy of 86%. 10 A dose of 20 mg iloprost was dissolved in 3 mls normal saline. This stock has been further diluted to obtain fluid samples of 3 ml containing approximately 3.3, 6.6, 9.9, 13.2, 16.5 or 20 mg iloprost.
Patients nebulised the iloprost solution over 5-8 min every 3 h with a night time break. The dose was gradually increased from approximately 3.3 mg up to a maximum dose of 20 mg/nebulisation over a period of 1 week in respect to the patients symptoms.
Finally, all patients received 7 nebulisations per day with a total dose of 140 mg/24 h consistent with a mouthpiece dose of 120 mg/24 h.
Short-term effects were assessed using peak expiration flow (PEF) (best of 3 readings) and percutaneous oxygen saturation (SO 2 ) measured before and after every nebulisation. Results were analysed as the mean change of either PEF or SO 2 after nebulisation in respect to the underlying disease and the dose of iloprost nebulised.
Long-term effects on pulmonary function and gas exchange were assessed by using spirometry and bodyplethysmography (Jaeger s , Wuerzburg, Germany) with analysis of forced expiratory volume in 1 s (FEV 1 ), forced vital capacity (FVC), total lung capacity (TLC), and residual volume (RV). The ratio between RV and TLC has been used as surrogate parameter for small airway function. 15, 16 Values are expressed as percent predicted using the reference values of the European Society for Coal and Steal (ESCS).
Gas exchange was assessed by measurement of diffusion capacity (Keogh factor) using the COsingle breath method corrected for haemoglobin and alveolar volume (Jaeger s , Wuerzburg, Germany). Furthermore, we measured SO 2 at rest and minimum SO 2 during 6 min walking test (6 MWT) as a sensitive parameter for exercise induced disturbance in gas exchange. 17 Results were expressed as mean change after 3 months from baseline and analysed concerning underlying disease.
As data were normally distributed, results are expressed in mean (7standard deviation). Analysis for statistically significant differences was performed using paired t-test.
Results
Short-term effects were analysed in all 65 patients with a mean pre-nebulisation PEF of 423798 and mean post nebulisation of PEF 415798 with a mean change of À1.9%. There were no clinically or statistically significant differences concerning the underlying diagnoses or the iloprost dosage (Tables  1 and 2 ). Mean SO 2 before nebulisation was 9076% and after nebulisation 9175% with a mean change of +0.7% without clinically or statistically significant differences concerning the underlying diagnoses or the iloprost dosages (Tables 1 and 2) .
Among the study population, 23 patients presented with an obstructive pattern in pulmonary function tests displayed by an FEV 1 /FVC ratio o70% according to the GOLD criteria.
14 In these patients, mean PEF decreased by À1.7% from 336 (81) to 331 (84), whereas SO 2 changed by +2.0% from 87 (7) to 89 (5)%. During initiation of therapy the majority of patients experienced typical side effects including flushing, headaches, jaw pain, nausea, and leg cramps, which disappeared during continuous therapy.
Within the first 3 months of treatment, 15 patients stopped treatment with nebulised iloprost, among them 4 patients due to persistent and severe side effects, especially headaches and nausea during initiation phase of treatment despite dose reduction. Three patients were non-compliant with frequent nebulisations. Two patients developed severe dyspnoea and wheezing due to bronchoconstriction after 2 and 4 weeks after initiation of therapy. They recovered immediately after stop of nebulisations. Six patients underwent pulmonary thromboendarterectomy for CTEPH and received nebulised iloprost as bridging to surgery. Forty-eight patients completed the 3 months follow up including repeat PFT, 6 MWT and right heart catheterisation. There was a significant increase in 6 min walking distance from 2467113 to 2947115 m; however no significant change in resting haemodynamics. The increase in functional capacity was detected in all subgroups of patients. Data are shown in Tables 3 and 7. At baseline, mean FEV 1 and FCV were reduced with 747720% pred. and 86724% pred., respectively. The mean FEV 1 /FVC ratio was 86%. Mean TLC was marginally reduced with 93718% pred., whereas the RV was increased by 114724% pred. After 3 months treatment, there was a change of mean FEV 1 of À0.2%, mean FVC of +1.3%, mean TLC of +2.5%, and mean RV of +3.9%. Ratio of RV/TLC as surrogate parameter for small airway dysfunction was normal with 40% at baseline with minimal change after 3 months treatment.
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There were no statistically significant differences in the whole study population as well as the different diagnoses groups. Details are shown in Table 4 .
Concerning gas exchange, Keogh factor at baseline was reduced at 70723% pred., as well as SO 2 at rest with 9276%, and minimum. SO 2 during 6 MWT with 83712%. After 3 months treatment there was a mean change in Keogh factor by À1.9%. SO 2 at rest changed in mean by +1.7%. Assessing the minimum SO 2 during 6 MWT, there was a mean change of +0.1% after 3 months. Details are shown in Table 5 . There were no statistically significant differences in the whole study population as well as the different diagnoses groups comparing baseline and 3 months follow-up parameters. 

Discussion
In this study, we found neither short-nor long-term systematic adverse effects on pulmonary function test or gas exchange in patients with pulmonary hypertension of different origin. Two patients with underlying obstructive lung disease developed broncoconstriction on treatment with nebulised iloprost with recovery after cessation of therapy, accounting for about 9% of patients with underlying obstructive lung disease in our series. As any inhaled compound may provoke bronchial irritant effects, especially in these patients a routine pulmonary function testing should be performed at follow-up. At baseline patients presented with a slight reduction in lung volumes, consistent with a recent report about impaired peripheral airway function in patients with primary pulmonary hypertension. 5 In long-term follow-up, there were no significant changes in FEV 1 , FVC, TLC and RV indicating no significant obstructive or restrictive changes, or hyperinflation. 18, 19 For assessment of gas exchange, we used minimum SO 2 before and after inhalation for easy and rapid assessment of short-term effects on oxygenation. For long-term changes the CO-diffusion capacity corrected for alveolar volume and haemoglobin was used as the most sensitive and comprehensive parameter. Furthermore, minimum SO 2 during 6 MWT reflects oxygenation status during exercise. 17, 18 Our data indicate that nebulised iloprost is not associated with short-or long-term adverse effect on pulmonary gas exchange in patients with pulmonary hypertension of different origin. There was a tendency toward better SO 2 at rest and during exercise in the RD group, however this was not statistically significant (Table 5) . Only in one study in patients with pulmonary hypertension due to lung fibrosis there was an insignificant reduction of SaO 2 after acute inhalation of prostacyclin. 3 In our study, 3 months treatment resulted in a significant increase in 6 MWD of 48 m in the whole study population, comparable to the result of the randomised controlled trial on nebulised iloprost in pulmonary hypertension with a mean increase in 6 MWD of 36 m after 3 months treatment. 1 Treatment with nebulised iloprost demands a commitment, as 7 nebulisations per day are required, and compliance problems are inevitable. 18 So far, data concerning compliance with treatment and severity of side effects in chronic use of nebulised iloprost are sparse. Typically, side effects occur pronounced during initiation phase of therapy. 1, 11, 12, 20 In our study, 3 patients stopped treatment due to non-compliance (4%). Furthermore, 4 patients stopped treatment due to severity of side effects during initiation of therapy (6%). This might be contributed by the relatively high dose of iloprost used, although appropriate dose reduction has been attempted in these patients. Concerning subgroup analysis, 50% of patients in the RD group stopped treatment due to side effects, and all of them had underlying COPD. Therefore, side effects due to probable airway irritation should be considered in these patients. (Tables 6 and 7 ).
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In total, 9 patients stopped treatment due to iloprost related side effects or non-compliance with frequent nebulisations (14%).
In conclusion, nebulised iloprost is an effective treatment in pulmonary hypertension of different origin without systematic adverse effects on pulmonary function test and gas exchange. A bronchoconstrictive effect might develop in patients with underlying obstructive lung disease. In our study, 14% of patients stopped treatment due to side effects or non-compliance. 
